Which Insulin Brand Has Disappeared From the Market?
The brand at the centre of the current concern is Apidra, a rapid-acting insulin manufactured by Sanofi. Its active ingredient is insulin glulisine, which helps control blood sugar levels, particularly around mealtimes.
According to a statement reported by health authorities, Apidra is unavailable because of international supply constraints. The disruption has raised concerns among patients who have been using this particular insulin as part of their prescribed diabetes management plan.
For patients who have relied on the same brand for a long time, its sudden disappearance from pharmacies can be stressful. Finding a replacement is not simply a matter of choosing another product from the shelf. Insulin treatment needs to be managed carefully to maintain stable blood glucose levels.
Government Says Alternative Insulin Brands Are Available
The Ministry of Health has sought to reassure patients by stating that alternative rapid-acting insulin products remain available across Pakistan.
The two alternatives identified by the ministry are:
NovoRapid, manufactured by Novo Nordisk, contains insulin aspart.
Humalog, manufactured by Eli Lilly, contains insulin lispro.
Both belong to the rapid-acting insulin group. However, this does not mean patients should automatically replace Apidra with either product. The appropriate choice and dosage depend on an individual's treatment plan and medical needs.
Health authorities have also stated that other major categories of insulin remain accessible. Nevertheless, the availability of alternatives should be confirmed locally, as stock can vary between pharmacies, cities and healthcare facilities.
Why Is Insulin So Important for Diabetes Patients?
Insulin is an essential medicine for people with type 1 diabetes because their bodies cannot produce enough insulin to regulate blood glucose. Many people with type 2 diabetes also require insulin when other treatments are insufficient.
Without appropriate insulin treatment, blood sugar can rise to dangerous levels. In people who depend on insulin, missing doses can lead to serious complications, including diabetic ketoacidosis, a potentially life-threatening emergency.
That is why any interruption in insulin supplies deserves immediate attention. Even when alternative brands are available, patients need reliable information and timely medical guidance to avoid unnecessary risks.
Pakistan's Large Diabetes Burden Adds to the Concern
Pakistan faces a major public health challenge because of its large population living with diabetes.
Recent estimates from the International Diabetes Federation put the number of adults living with diabetes in Pakistan at approximately 34 million. This means that disruptions in the availability or affordability of essential diabetes medicines can affect a substantial number of households.
For many families, managing diabetes already involves regular medical appointments, glucose monitoring, dietary adjustments and the ongoing cost of medicines. When a prescribed insulin brand becomes difficult to find, patients may face additional stress and uncertainty.
The latest disruption has also renewed questions about Pakistan's dependence on international pharmaceutical supply chains and the need for consistent access to essential medicines.
What Should Patients Do if Apidra Is Unavailable?
Doctors and health authorities have advised patients using Apidra to consult their healthcare provider before changing their insulin regimen. Switching formulations may require dose adjustments and closer blood glucose monitoring.
Patients should follow several precautions:
Do not stop insulin treatment on your own. Interrupting prescribed insulin can be dangerous.
Do not switch brands or calculate a replacement dose yourself. Ask your treating doctor or diabetes specialist to determine the appropriate alternative.
Check availability with licensed pharmacies. Ask whether the prescribed product is available and seek guidance from your healthcare provider if it is not.
Monitor blood glucose as advised. Follow your clinician's instructions during any change in treatment.
Seek urgent medical care if serious symptoms develop. Vomiting, abdominal pain, deep or rapid breathing, confusion or severe weakness may indicate a medical emergency.
These precautions are particularly important for people with type 1 diabetes, who require continuous access to appropriate insulin treatment.
A Wider Question About Medicine Supply in Pakistan
The Apidra disruption has drawn attention to a broader issue: the reliability of essential medicine supplies in Pakistan.
In August 2025, the Pakistan Medical Association warned that numerous essential medicines were missing from the market, including some products used to treat serious and chronic illnesses. Such reports have highlighted concerns about supply chains, manufacturing costs, imports and the availability of affordable alternatives.
Although the current Apidra situation has been attributed to international supply constraints, it demonstrates why dependable medicine distribution is important. Patients should not have to wait until a medicine disappears from pharmacy shelves before clear information about alternatives and supply arrangements becomes available.
Improving local manufacturing capacity, maintaining adequate stocks and providing timely public updates could help reduce the impact of future disruptions.
0 Comments